Innovative evaluation of selinexor and JQ1 synergy in leukemia therapy via C-MYC inhibition
Selinexor and JQ1 synergistically target AML by dual C-MYC inhibition, offering a promising strategy to overcome resistance. Further clinical evaluation is warranted.
Authors
- Tingfen Deng
- Jiaqi Fan (ORCID: https://orcid.org/0000-0001-9757-5721)
- Peihong Wang (ORCID: https://orcid.org/0000-0002-6899-8765)
- Chuhong Hu
- Shunqing Wang (ORCID: https://orcid.org/0000-0001-9418-4901)
- Jiajun He (ORCID: https://orcid.org/0009-0003-8587-3686)
- Yong Dai
- Yanli Xu
Institutions
- Sun Yat-sen University (CN)
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Guangzhou Blood Center (CN)
- Guangzhou First People's Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-05-08
- DOI
- https://doi.org/10.1186/s12967-025-06525-z
- Citations
- 4
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 3.22
Funders
- National Natural Science Foundation of China
- Guangzhou Municipal Science and Technology Project
- Key Technologies Research and Development Program